Wisconsin Patent of the Month – May 2024

NitricGen, Inc. is developing a novel gaseous nitric oxide (NO) delivery system, the eNOGenerator, for the treatment of slow or difficult to heal wounds. This newly patented system offers a method for generating NO in controlled and accurate amounts with low levels of impurities. NO, with its myriad applications in both biological and medical domains, has long been sought after for its beneficial effects, ranging from promoting plant growth to treating various medical conditions.

Traditionally, methods for generating NO have been limited by challenges such as electrode wear, impurity formation, and inefficiency. NitricGen addresses these limitations head-on, providing a solution that not only produces NO reliably but also ensures precise control over its concentration and flow rate.

At the heart of NitricGen’s invention lies an innovative approach to electric discharge plasma reactions, leveraging controlled pulses of electricity across electrodes to induce the production of NO  from an oxygen-nitrogen gas mixture. Unlike previous methods, NitricGen’s electronic control circuit allows for independent regulation of pulse frequency and duration, offering unparalleled flexibility and accuracy in NO generation.

One of the key advantages of NitricGen is its ability to produce NO efficiently without excessive electrode wear or impurity formation. By optimizing the electric discharge process, NitricGen minimizes energy consumption while maximizing NO output, resulting in a more cost-effective and environmentally friendly solution.

NitricGen incorporates advanced sensing technology to monitor the electric discharge process in real-time, ensuring consistent and reliable NO production. This eliminates the need for cumbersome gas monitors, streamlining the operation and maintenance of the apparatus.

In medical applications, NitricGen holds immense promise for various treatments, including wound healing, anti-microbial therapy, and pulmonary vasodilation. By delivering nitric oxide in precise concentrations, NitricGen enables targeted and effective treatment strategies, improving patient outcomes and reducing the risk of adverse effects.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts